Effector Therapeutics Inc (EFTR) - Net Assets
Based on the latest financial reports, Effector Therapeutics Inc (EFTR) has net assets worth $827.00K USD as of March 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($27.13 Million) and total liabilities ($26.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EFTR cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $827.00K |
| % of Total Assets | 3.05% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 85.64 |
Effector Therapeutics Inc - Net Assets Trend (2019–2023)
This chart illustrates how Effector Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore EFTR total asset value for the complete picture of this company's asset base.
Annual Net Assets for Effector Therapeutics Inc (2019–2023)
The table below shows the annual net assets of Effector Therapeutics Inc from 2019 to 2023. For live valuation and market cap data, see how much is Effector Therapeutics Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-5.79 Million | -248.74% |
| 2022-12-31 | $3.90 Million | -77.46% |
| 2021-12-31 | $17.28 Million | +113.07% |
| 2020-12-31 | $-132.25 Million | -855.60% |
| 2019-12-31 | $-13.84 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Effector Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2846700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $173.58 Million | % |
| Total Equity | $-5.79 Million | 100.00% |
Effector Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Effector Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank Cimb Niaga Tbk
JK:BNGA
|
$946.26 |
|
Invesque Inc
TO:IVQ
|
$956.23 |
|
Carzo Holdings Bhd
KLSE:03048
|
$958.49 |
|
LD + HOUSES PCL FGN BA 1
F:LHOG
|
$988.96 |
|
Internet Thailand Public Company Limited
F:IE2A
|
$933.05 |
|
Green & Gold Minerals Ltd
AU:GG1
|
$908.12 |
|
Grom Social Enterprises Inc
NASDAQ:GROM
|
$902.16 |
|
China New Higher Education Group Limited
STU:8CN
|
$862.60 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Effector Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 3,896,000 to -5,795,000, a change of -9,691,000 (-248.7%).
- Net loss of 35,811,000 reduced equity.
- New share issuances of 15,031,000 increased equity.
- Other comprehensive income increased equity by 18,000.
- Other factors increased equity by 11,071,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.81 Million | -617.96% |
| Share Issuances | $15.03 Million | +259.38% |
| Other Comprehensive Income | $18.00K | +0.31% |
| Other Changes | $11.07 Million | +191.04% |
| Total Change | $- | -248.74% |
Book Value vs Market Value Analysis
This analysis compares Effector Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-250.86 | $0.00 | x |
| 2020-12-31 | $1.64 | $0.00 | x |
| 2021-12-31 | $10.70 | $0.00 | x |
| 2022-12-31 | $2.37 | $0.00 | x |
| 2023-12-31 | $-2.65 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Effector Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (242.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.36 Million |
| 2020 | 1451.58% | 33.84% | 2.51x | 17.06x | $14.11 Million |
| 2021 | 91.40% | 1104.76% | 0.03x | 3.13x | $14.07 Million |
| 2022 | -331.80% | -363.83% | 0.12x | 7.46x | $-13.32 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-35.23 Million |
Industry Comparison
This section compares Effector Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,740,057
- Average return on equity (ROE) among peers: -43.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Effector Therapeutics Inc (EFTR) | $827.00K | 0.00% | 31.81x | $940.00 |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $60.67K | -43.96% | 0.04x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.74 Billion |
About Effector Therapeutics Inc
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and a… Read more